Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4224-4235

  Kostova, Maya B ^a   Rosen, D Marc ^a   Chen, Ying ^a   Mease, Ronnie C ^a   Denmeade, Samuel R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; IODINE 125; PEPTIDOMIMETIC AGENT; PHENYLALANINE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROSTATE CANCER; RADIOIODINATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BORONIC ACIDS; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; PEPTIDOMIMETICS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879063764     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301718c     Document Type: Article

References (48)

1. Watt, K. W.; Lee, P. J.; M'Timkulu, T.; Chan, W. P.; Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 3166-3170 (Pubitemid 16042997)
2. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein J. Clin. Invest. 1985, 76, 1899-1903 (Pubitemid 16196061)
3. Yousef, G. M.; Diamandis, E. P. An overview of the kallikrein gene families in humans and other species: emerging candidate tumor markers Clin. Biochem. 2003, 36, 443-452 (Pubitemid 37083557)
4. Williams, S. A.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007, 67, 312-329
5. Denmeade, S. R.; Sokoll, L. J.; Chan, D. W.; Khan, S. R.; Isaacs, J. T. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostatic cancer xenograft models Prostate 2001, 48, 1-6 (Pubitemid 32545071)
6. Lilja, H.; Christensson, A.; Dahlen, U.; Matikainen, M. T.; Nilsson, O.; Pettersson, K.; Lovgren, T. Prostate-specific antigen in serum occurs predominantly in complex with a1-antichymotrypsin Clin. Chem. 1991, 37, 1618-1625 (Pubitemid 21905228)
7. Stenman, U. H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. A complex between prostate specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Res. 1991, 51, 222-226
8. Denmeade, S. R.; Jakobsen, C.; Janssen, S.; Khan, S. R.; Lilja, H.; Christensen, S. B.; Isaacs, J. T. Prostate-specific antigen (PSA) activated thapsigargin prodrug as targeted therapy for prostate cancer J. Natl. Cancer Inst. 2003, 95, 990-1000 (Pubitemid 36896716)
9. Williams, S. A.; Merchant, R. F.; Garrett-Mayer, E.; Isaacs, J. T.; Buckley, J. T.; Denmeade, S. R. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease J. Natl. Cancer Inst. 2007, 99, 376-385 (Pubitemid 47073481)
10. Ulmert, D.; Evans, M. J.; Holland, J. P.; Rice, S. L.; Wongvipat, J.; Pettersson, K.; Abrahamsson, P. A.; Scardino, P. T.; Larson, S. M.; Lilja, H.; Lewis, J. S.; Sawyers, C. L. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen Cancer Discovery 2012, 2, 320-327
11. LeBeau, A. M.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Prostate-specific antigen is a 'chymotrypsin-like' serine protease with unique P1 substrate specificity Biochemistry 2009, 48, 3490-3496
12. Denmeade, S. R.; Lou, W.; Malm, J.; Lovgren, J.; Lilja, H.; Isaacs, J. T. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen Cancer Res. 1997, 57, 4924-4930 (Pubitemid 27469004)
13. Singh, P.; LeBeau, A. M.; Lilja, H.; Denmeade, S. R.; Isaacs, J. I. Molecular insights into substrate specificity of prostate specific antigen through structural modeling Proteins 2009, 77, 984-993
14. LeBeau, A. M.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen Chem. Biol. 2008, 15, 665-674 (Pubitemid 351957911)
15. Matteson, D. S.; Michnick, T. J.; Willett, R. D.; Patterson, C. D. [(1 R)-1-Acetamido-3-(methylthuio)propyl]boronic acid and the X-ray structure of its ethylene glycol ester Organometallics 1989, 8, 726-729
16. Debaene, F.; Da Silva, J. A.; Pianowski, Z.; Duran, F. J.; Winssinger, N. Expanding the scope of PNA-encoded libraries: divergent synthesis of libraries targeting cysteine, serine and metalloproteases as well as tyrosine phosphatases Tetrahedron 2007, 63, 6577-6586 (Pubitemid 46817614)
17. Elgendy, S.; Patel.; Green, D.; Goodwin, C. A.; Scully, M. F.; Husman, W.; Skordalakes, E.; Kakkar, V. V.; Deadman, J. J. Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry Tetrahedron Lett. 1997, 38, 3305-3308 (Pubitemid 27193195)
18. Zhu, Y.; Zhao, X.; Zhu, X.; Wu, G.; Li, Y.; Ma, Y.; Yuan, Y.; Yang, J.; Hu, Y.; Ai, L.; Gao, Q. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates J. Med. Chem. 2009, 52, 4192-4199
19. Zhu, Y.; Yao, S.; Xu, B.; Ge, Z.; Cui, J.; Cheng, T.; Li, R. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors Bioorg. Med. Chem. 2009, 17, 6851-6861
20. Watanabe, T.; Abe, H.; Momose, I.; Takahashi, Y.; Ikeda, D.; Akamatsu, Y. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 5839-5842
21. Watanabe, T.; Momose, I.; Abe, M.; Abe, H.; Sawa, R.; Umezawa, Y.; Ikeda, D.; Takahashi, Y.; Akamatsu, Y. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 2343-2345
22. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 16789-16794 (Pubitemid 39601317)
23. Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, T. R.; Joachimiak, A.; Podjarny, A. D. Ultrahigh resolution drug design I: Details of interactions in human aldose reductase-inhibitor complex at 0.66 Å Proteins: Struct., Funct., Genet. 2004, 55, 792-804 (Pubitemid 38702939)
24. Dekker, B.; Keen, H.; Shaw, D.; Disley, L.; Hastings, D.; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124 Nucl. Med. Biol. 2005, 32, 403-413 (Pubitemid 40692690)
25. Nanus, D. M.; Milowsky, M. I.; Kostakoglu, L.; Smith-Jones, P. M.; Vallabahajosula, S.; Goldsmith, S. J.; Bander, N. H. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen J. Urol. 2003, 170, S84-S88 discussion S88-S89.
26. Smith-Jones, P. M.; Vallabahajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S. J.; Bander, N. H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor J. Nucl. Med. 2003, 44, 610-617 (Pubitemid 40003748)
27. Cohen, P.; Graves, H. C.; Peehl, D. M.; Kamarei, M.; Giudice, L. C.; Rosenfeld, R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma J. Clin. Endocrinol. Metab. 1992, 75, 1046-1053
28. Iwamura, M.; Hellman, J.; Cockett, A. T.; Lilja, H.; Gershagen, S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen Urology 1996, 48, 317-325 (Pubitemid 26279633)
29. Cramer, S. D.; Chen, Z.; Peehl, D, M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts J. Urol. 1996, 156, 526-531 (Pubitemid 126445373)
30. Dallas, S. L.; Zhao, S.; Cramer, S. D.; Chen, Z.; Peehl, D. M; Bonewald, L. F. Preferential production of latent transforming growth factor-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen J. Cell. Physiol. 2005, 202, 361-370 (Pubitemid 40041306)
31. Lilja, H.; Piironen, T. P.; Rittenhouse, H. G.; Mikolajczyk, S. D.; Slawin, K. M. Comprehensive Textbook of Genitourinary Oncology; Lippincott Williams and Wilkins Publishers: Philadelphia, 2000; pp 638-650.
32. Williams, S. A.; Jelinek, C. A.; Litvinov, I.; Cotter, R. J.; Isaacs, J. T.; Denmeade, S. R. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers Prostate 2011, 71, 1595-1607
33. O'Keefe, R. J.; Guise, T. A. Molecular mechanisms of bone metastasis and therapeutic implications Clin. Orthoped. Relat. Res. 2003, 415, S100-S104
34. Roodman, G. D. Mechanisms of bone metastasis N. Engl. J. Med. 2004, 350, 1655-1664
35. Ulmert, D.; Evans, M. J.; Holland, J. P.; Rice, S. L.; Wongvipat, J.; Pettersson, K.; Abrahamsson, P. A.; Scardino, P. T.; Larson, S. M.; Lilja, H.; Lewis, J. S.; Sawyers, C. L. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen Cancer Discovery 2012, 2, 320-327
36. Adlington, R. M.; Baldwin, J. E.; Becker, G. W.; Chen, B.; Cheng, L.; Cooper, S. L.; Hermann, R. B.; Howe, T. J.; McCoull, W.; McNulty, A. M.; Neubauer, B. L.; Pritchard, G. J. Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen J. Med. Chem. 2001, 44, 1491-1508 (Pubitemid 32852193)
37. Adlington, R. M.; Baldwin, J. E.; Chen, B.; Cooper, S. L.; McCoull, W.; Pritchard, G. J.; Howe, T. J.; Becker, G. W.; Hermann, R. B.; McNulty, A. M.; Neubauer, B L. Design and synthesis of novel monocyclic β-lactam inhibitors of prostate-specific antigen Bioorg. Med. Chem. Lett. 1997, 7, 1689-1694 (Pubitemid 27321485)
38. Knight, W. B.; Green, B. G.; Chabin, R. M.; Gale, P.; Maycock, A. L.; Weston, H.; Kuo, D. W.; Westler, W. M.; Dorn, C. P.; Finke, P. E. Specificity, stability, and potency of monocyclic β-lactam inhibitors of human leukocyte elastase Biochemistry 1992, 35, 8160-8170
39. Green, B. G.; Chabin, R.; Mills, S.; Underwood, D. J.; Shah, S. K.; Kuo, D.; Gale, P.; Maycock, A. L.; Liesch, J.; Burgey, C. S.; Doherty, J. B.; Dorn, C. P.; Finke, P. E.; Hagmann, W. K.; Hale, J. J.; MacCoss, M.; Westler, W. M.; Knight, W. B. Mechanism of inhibition of human leucocyte elastase by β-lactams. Stability, reactivation kinetics, and products of β-lactam-derived E-I complexes Biochemistry 1995, 44, 14331-14243
40. Huang, A.; Knoell, C.; Fey, G.; Hazegh-Azam, M.; Tashjian, A.; Hedstrom, L.; Abeles, R. H. Modulation of recombinant human prostate-specific antigen: activation by hofmeister salts and inhibition by azapeptides Biochemistry 2001, 40, 11734-11741 (Pubitemid 32906035)
41. Koistinen, H.; Wohlfart, G.; Mattsson, J. M.; Wu, P.; Lahdenpera, J.; Stenman, U. H. Novel small molecule inhibitors for prostate-specific antigen Prostate 2008, 68, 1143-1151
42. Mikolajczyk, A. D.; Marks, L. S.; Partin, A. W.; Rittenhouse, H. G. Free prostate-specific antigen is becoming more complex Urology 2002, 59, 797-802 (Pubitemid 34522163)
43. Matteson, D. S.; Sadhu, K. M.; Lienhard, G. E. R -1-Acetamido-2- phenylethaneboronic acid. A specific transition-state analog for chymotrypsin J. Am. Chem. Soc. 1981, 103, 5241-5242
44. Matteson, D. S.; Sadhu, K. M. Synthesis of 1-amino-2-phenylethane-1- boronic acid derivatives Organometallics 1984, 3, 614-618
45. Matteson, D. S.; Jesthi, P. K.; Sadhu, K. M. Synthesis and properties of pinanediol α-amido boronic esters Organometallics 1984, 3, 1284-1288
46. Hansen, K. K.; Grosch, B.; Greiveldinger-Poenaru, S.; Bartlett, P. A. Synthesis and evaluation of macrocyclic transition state analog inhibitors for α-chymotrypsin J. Org. Chem. 2003, 68, 8465-8470 (Pubitemid 37329106)
47. Wityak, J.; Earl, R., A.; Abelman, M. M.; Bethel, Y. B.; Fisher, B. N.; Kauffman, G. S.; Kettner, C. A.; Ma, P.; McMillan, J. L.; Mersinger, L. J.; Pesti, J.; Pierce, M. E.; Rankin, F. W.; Chorvat, R. J.; Confalone, P. N. J. Org. Chem. 1995, 60, 3717-3722
48. Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castanares, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer J. Med. Chem. 2008, 51, 7933-7943